GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announces its revised outlook for 2024 and reflects on recent progress.
GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announces its revised outlook for 2024 and reflects on recent progress.